Switzerland and Canada mark the first market entries for Formycon’s ranibizumab biosimilar this year, with several anticipated launches in the Middle East later in 2024.

Pink Sheet’s Drug Review Profile explores Amgen’s Wezlana, an interchangeable biosimilar to Janssen’s Stelara. FDA determined late in the review that switching studies generally would not be needed for interchangeable ustekinumab products, prompting Amgen to seek the designation.

Formycon has announced the approval of its biosimilar ranibizumab by Health Canada, with commercial launch by Teva expected to begin in Q1 next year.

US FDA India country director Dr Sarah McMullen provides a fact check at a recent conclave to dispel the notion that interchangeable biosimilars are safer and more effective than other approved biosimilars.